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Objective: To determine the levels of NT-pro BNP in HIV patients over 40 years who are receiving highly active
antiretroviral therapy (HAART) and investigating potential independent clinical or laboratory factors.
Method: We determine levels of NT-pro BNP in peripheral blood of HIV patients from Costa del Sol Hospital,
over 40 years.
We collected epidemiological, classical cardiovascular risk factors and variables associated with HIV infection
status. The qualitative variables were compared using the χ2 test. NT-proBNP levels were taken as the dependent
variable. The association between these levels and the quantitative variables were studied by analysis of variance
(ANOVA), and the association with the qualitative variables, using Student’s t test.
Results: Nt-pro BNP levels were determined in 146 HIV patients. We assess the 10-year cardiovascular risk calculated by
the Framingham equation, 59 (41.5%) were classified as low risk, 46 (32.4%) as a moderate risk and 37 (26.1%) as a high
risk. The higher levels of NT-pro BNP were found in women, and in those patient with lower filtration rate and high
levels of triglycerides. An association was also observed between higher levels of NT-proBNP and the recent use of
lamivudine and fosamprenavir. After a multivariate analysis we found an association between higher levels of NT-proBNP
and the current use of fosamprenavir and a lower glomerular filtration rate.
Conclusions: We found, with the limitations of a small serie, that higher levels of NTproBNP in HIV patients could be
linked to the occurrence of cardiovascular events, this fact suggest that NTpro BNP could be used in patients at
moderate or high vascular risk in order to optimise the primary prevention of vascular events.
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Older population cohorts in HIV patients have expanded
considerably in recent years [1,2], so the infection is in-
creasingly accompanied by age-associated comorbidities,
including cardiovascular events (Ischaemic heart disease,
stroke, heart failure or peripheral artery disease) [3].
These comorbidities are gaining increansing import-
ance in mortality rates of patients infected with HIV [4].
According to several authors it seems clear that the inci-
dence of cardiac ischaemic events is higher among
patients with HIV infection compared to those who are
uninfected, and even more in those who are receiving
highly active antiretroviral therapy (HAART) [5]. On the* Correspondence: elenacrespog@gmail.com
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unless otherwise stated.other hand there is a study in which proves that CV events
were higher among those who were not receiving HAART
[6]. In part, this fact (the correlation of CV risk and treat-
ment) is attributed to the use, whether recent or cumula-
tive, of certain nucleoside analogues (abacavir, didanosine)
and protease inhibitors (lopinavir, fosamprenavir (fAPV)).
Furthermore, it has recently been determined that
the incidence of heart failure is almost twice as high
among patients with HIV infection than in those un-
infected patients, and it is comparable to traditional risk
factors such as hypertension or diabetes [7]. Again, this
increased incidence of heart failure has been linked to
antiretroviral treatment, and specifically to the recent use
of tenofovir (TDF) in one study [8]. Use of protease inhibi-
tors has been related with another surrogate marker of
vascular disease, the ankle-branch index [9].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is secreted by ventricular myocytes in response to pres-
sure overload on the ventricular wall. Once BNP has
been segregated, it divides into an active peptide and the
N terminal fragment of BNP (NT-proBNP).
Studies have established the value of BNP and of NT-
proBNP in the diagnosis and prognosis of ventricular
dysfunction and in the prognosis of acute coronary syn-
dromes [10-12]. It is considered a risk marker of vascu-
lar events in the general population [13] and also in
patients with HIV infection [14].
However, few studies have focused on determining
levels of NT-proBNP in patients with HIV infection, re-
lating them to increased systolic pressure in the pulmon-
ary artery [15] and the presence of comorbidities [16].
There is also some evidence that ART could be involved
in increased left ventricular mass, and thus an analysis
of these biomarkers could provide an additional prog-
nostic measure for our patients [17].
In this paper, we explore the hypothesis that ART or
one or more of its components might be associated with
higher levels of NT-proBNP.
Material and Methods
The patients were part of a previous research series [16]
created to study the left ventricular mass in patients with
HIV infection. The patients in this serie who were aged
over 40 years were invited to cooperate in the present
study, to determine levels of NT-proBNP in peripheral
blood. When consent was given, a serum sample was ex-
tracted, frozen to −70°C and stored until needed for the
NT-proBNP analysis.
NT-proBNP (amino acid residues 1–76) was measured
using the Dimension RxL Max Analyzer (Siemens), lower
limit of detection 10 ng/l. For all patients, epidemiological
such as age and gender, and clinical (duration of HIV, dur-
ation of ART, BMI…) data were compiled, together with
the classical cardiovascular risk factors and variables asso-
ciated with HIV infection status.
These aspects are described in detail in the descriptive
part of the series as a whole.
Statistical analysis
Data were collected directly in SPSS 15.0 (Statistical
Package for the Social Sciences, Inc. Chicago, Illinois,
USA).
The quantitative variables were described using the
mean with a 95% confidence interval (95% CI), and the
qualitative variables were expressed as percentages.
The qualitative variables were compared using the χ2
test. NT-proBNP levels were taken as the dependent
variable. The association between these levels and the
quantitative variables were studied by analysis of vari-
ance (ANOVA), and the association with the qualitativevariables, using Student’s t test, after verifying the nor-
mal distribution of the samples; when this condition was
not fulfilled, the Mann–Whitney U test was applied.
The variables that presented a statistically significant
association with NT-proBNP levels (p < 0.05) were in-
cluded in the multivariate analysis, using a forward step-
wise method. Statistical significance was set at p < 0.05.Results
Characteristics of the participants
NT-proBNP levels were determined in 146 patients. The
main characteristics of the participants in the study are
shown in Table 1.
The main route of acquisition of infection was the use
of injected drugs (34.9%), followed by heterosexual con-
tact (32.2%) and homosexual contact (27.4%).
A total of 56 patients had HCV coinfection (38.4%),
and 24 (16.4%) had HBV coinfection.
With respect to the classical risk factors, 11 patients
(7.5%) were diabetic, 21 (14.4%) had hypertension, 40
(27.4%) had dyslipidaemia and 78 (53.4%) were current
smokers. Nine patients (8.2%) had prior vascular disease:
of these, five had cerebrovascular disease, three had is-
chaemic heart disease and one had peripheral arterial
disease. Seven patients had a family history of cardio-
vascular disease. Nine (6.2%) were receiving concomi-
tant antiplatelet therapy, ten (6.8%) were being treated
with beta-blockers, six (4.1%) with ACE inhibitors
(angiotensin-converting-enzyme inhibitors), five (3.5%)
with ARA-II (angiotensin II receptor antagonists),
twenty (13.7%) with statins, ten (6.8%) with fibrates and
five (3.4%) with metformin.
In regard to the 10-year cardiovascular risk calculated
by the Framingham equation, 59 (41.5%) were classed as
low risk, 46 (32.4%) moderate risk and 37 (26.1%) high
risk, with an average risk of a vascular event within
10 years of 14.81%.
The levels of NT-proBNP (pg/mL) were observed to
be higher among the women than in men (81.6 vs.
65.32, p = 0.002). Older age was also associated with
higher levels of NT-proBNP (p = 0.005) but it was not
related to duration of HIV or ART.
There was no difference between treatment-naive and
experienced patients (28.19 vs. 74.27, p = 0.1). With re-
spect to the analytical parameters, no relation was found
with the nadir CD4 level or the level at the time of the
study, nor with detectability. Levels of NT-proBNP were
higher among the patients with a lower glomerular fil-
tration rate (p = 0.028) and among those with higher
levels of triglycerides (p = 0.005).
An association was also observed between higher
levels of NT-proBNP and the recent use of Lamivudine
(3TC) (51.55 vs. 108.89, p = 0.02) and fosamprenavir
Table 1 Main characteristics of the patients included in
the study
Parameter
Male sex 111 (76%)
Age, years 50.14 (48.79-51.50)
Duration of HIV infection, years 10.61 (9.47-11.74)
Duration of ART, years 7.02 (6.16 - 7.88)
Naïve 16 (11%)
Nadir CD4 lymphocyte count 260.39 (222.01 - 298.77)
CD4 lymphocyte count at the time
of the study
633.66 (581.99-685.33)
VIH-1 viral load <50 copies/mL 108 (74%)
Glomerular filtrate (mL/min) 105.03 (100.67-109.39)
Total cholesterol (mg/dL) 196.97 (189.82-204.13)
HDL cholesterol (mg/dL) 49.42 (46.78-52.06)
LDL cholesterol (mg/dL) 116.96 (110.92-122.99)
Triglycerides (mg/dL) 167.28 (149.43-185.12)
BMI 24.76 (24.05-25.46)
Systolic BP (mmHg) 129.32 (126.21-132.44)
Diastolic BP (mmHg) 77.65 (75.63-79.67)
10-year cardiovascular event risk (%) 14.81 (12.96-16.66)
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of TDF and lower levels of NT-proBNP (89.61 vs. 51.45,
p = 0.04), but no other association was found with the
recent use of any antiretroviral.
Multivariate analysis was performed, including levels
of NT-proBNP as the dependent variable, with the inde-
pendent variables being the glomerular filtration rate,
triglyceride levels, RV10 (vascular risk) and the current
use of 3TC, TDF and fAPV.
Higher levels of NT-proBNP were associated with the
current use of fAPV (p < 0.005) and a lower glomerular
filtration rate (p < 0.0005).Discussion
In our series of HIV patients aged over 40 years, an as-
sociation was found between the current use of fosam-
prenavir and higher levels of NTproBNP and between
lower levels of glomerular filtrate and higher levels of
NTproBNP.
In both cases there may be a biologically plausible ex-
planation. Lower levels of glomerular filtrate is a marker
of vascular risk and, in many cases, an expression of
subclinical organ injury.
In the French cohort [18], the recent use of fosampre-
navir was associated with a higher incidence of acute
myocardial infarction. There is increasing concern about
cardiovascular morbidity and mortality in patients with
HIV infection, and about this fact specific guides to riskmanagement have been published and various studies
were conducted to elucidate the role that some compo-
nent of HAART may have in ischaemic events.
In that area, it seems a useful strategy to determine
biomarkers such as NT-proBNP in subgroups of patients
at particular risk (the elderly or those with classical car-
diovascular risk factors) to evaluate the cardiovascular
safety of antiretroviral drugs, in order to anticipate, as
far as possible, the occurrence of ischaemic events.
The linear relationship of NT-proBNP with cardiovas-
cular events could make it a good surrogate marker.
High levels of NT-proBNP in HIV population have been
associated with the presence of comorbidities in women.
In the study by Mansoor [16], NTproBNP levels in the
general population were found to be associated with the
presence of anaemia and renal dysfunction. In the case of
women infected with HIV, no relation with the use of
HAART was found. However, of the 454 infected women
who participated in the study, only 60% were receiving
HAART at the time of the analytical determination, com-
pared to 89% in our study, this fact makes our study par-
ticularly suitable for detecting differences between those
who receive antiretroviral treatment and those who do
not. In the Spanish study by Serrano-Villar [19], an associ-
ation was found between higher levels of NT-proBNP and
increased intima-media thickness. In the present study,
measurements were not conducted specifically to detect
subclinical vascular disease, but studies such as the one
mentioned advocate the use of NTproBNP as a surrogate
marker of vascular disease. Duprez et al. [14] reported a
higher risk of cardiovascular events among patients with
HIV infection and higher levels of NT-proBNP than
among those with lower levels. This relationship was con-
trolled using traditional cardiovascular risk factors and
other biomarkers such as highly sensitive C-reactive pro-
tein and D-dimer.
We acknowledge that our study is a cross-sectional
one with a small sample size, and thus insufficient to
draw firm conclusions; nevertheless, it is striking that
even in this small series the factors associated with
higher levels of NT-proBNP are those which could be
linked to the occurrence of cardiovascular events.Conclusions
Even in this small serie, the factors associated with higher
levels of NTproBNP are those which could be linked to
the occurrence of cardiovascular events. This strongly sug-
gests the usefulness of determining these levels, at least in
subgroups at particular risk of such events.
According to our data higher levels of NT-proBNP
were found among lower glomerular filtration rate and
those using fAPV, on the other hand lower levels are in
relation with the recent use of TDF.
Olalla et al. AIDS Research and Therapy  (2015) 12:17 Page 4 of 4Biomarkers such as NT-proBNP might be used in pa-
tients at moderate or high vascular risk in order to opti-
mise the primary prevention of vascular events and
perhaps even to optimise antiretroviral therapy.
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